Public Health Agency of Canada CORONAVIRUS HOTLINE 1-833-784-4397

Facebook  Twitter  LinkedIn  youtube

Members Area
Resources Resources Open
Chapters Chapters Close
Site Map Site Map Open
Resources / Publications
Resources / Publications

News and Journal Articles

Twitter

You can follow us onTwitter or Facebook; our posts are shared on both sites.
TwitterFacebook YouTube

  Quick links to other helpful websites.
 

Johns Hopkins University
COVID-19 Global Cases

Government of Canada
COVID-19 Outbreak update
Coronavirus Disease COVID-19

World Health Organization
Coronavirus COVID-19 Outbreak
also
Online Course: Infection Prevention and Control (IPC) for Novel Coronavirus (COVID-19)

Centres for Disease Control and Prevention
Coronavirus COVID-19 

IPAC Canada Webinars:
COVID-19: Past Present & Future
also
N95 Respirator vs Surgical Mask Clinical Data: Informing respiratory protection policy.

Coronavirus (COVID-19) SARS-CoV-2

Public Health Agency of Canada
CORONAVIRUS HOTLINE 1-833-784-4397

Coronaviruses are a large family of viruses that may cause a range of illnesses in humans, from the common cold to SARS. Viruses of this family also cause a number of animal diseases.

Pandemic Coronavirus (COVID-19)

On December 31, 2019 the WHO China Country Office was informed of cases of pneumonia of unknown etiology detected in Wuhan City, Hubei Province of China. The outbreak began in a seafood and poultry market in Wuhan, a city of 11 million in central China. Like SARS-CoV and MERS-CoV, the newly detected coronavirus (SARS CoV-2) has a zoonotic source, however, human to human transmission has been confirmed. On March 11, 2020 the WHO declared COVID-19 viral disease a pandemic.

Epidemiology of COVID-19

As of March 4, 2021 total of 115,597,805 confirmed cases caused by the novel Coronavirus COVID-19 (SARS-CoV-2) and 2,569,011 deaths were reported. At this time 192 countries are reporting cases of the novel Coronavirus. For a full listing of affected countries refer to Coronavirus (COVID-19) Global Cases (Johns Hopkins University)

Source: Coronavirus (COVID-19) Global Cases (Johns Hopkins University).

Other Global COVID-19 Case Trackers


Canadian Cases COVID-19

As of March 4, 2021, a total of 878,391 confirmed cases caused by the novel Coronavirus COVID-19 (SARS-CoV-2) and 22,151 deaths were reported in Canada. An Epidemiological Summary of COVID-19 Cases in Canada is available.

For real time information refer to the:

PHAC Coronavirus Map of Canada

Provided by: Public Health Agency of Canada


Areas in Canada with cases of COVID-19 as of March 4, 2021
Location Total cases Active cases Recovered Deaths Tested
Count Rate* Count Rate* Count Count Rate* Count Rate
Canada 878,391 2,311 29,903 79 826,337 22,151 58 24,763,481 651,581
Newfoundland and Labrador 1,002 192 125 24 871 6 1 200,101 383,260
Prince Edward Island 138 86 23 14 115 0 0 109,360 685,106
Nova Scotia 1,649 168 29 3 1,555 65 7 350,135 357,517
New Brunswick 1,443 185 37 5 1,378 28 4 239,229 306,125
Quebec 290,377 3,386 7,379 86 272,553 10,445 122 6,320,910 737,169
Ontario 304,757 2,068 10,309 70 287,424 7,024 48 11,017,094 747,732
Manitoba 32,051 2,324 1,143 83 30,005 903 65 536,934 389,291
Saskatchewan 29,220 2,479 1,422 121 27,407 391 33 581,914 493,699
Alberta 134,785 3,048 4,613 104 128,261 1,911 43 3,425,265 774,618
British Columbia 82,473 1,602 4,808 93 76,289 1,376 27 1,950,778 378,960
Yukon 72 171 0 0 71 1 2 8,187 194,688
Northwest Territories 42 93 1 2 41 0 0 14,743 326,454
Nunavut 369 938 14 36 354 1 3 8,755 222,474

Source: Coronavirus disease (COVID-19) Government of Canada


About COVID-19

The first human infections in China must have occurred in November 2019 or earlier. The first 59 suspected cases at the end of December 2019 and early January 2020 were admitted to Jinyintan Hospital, which was specially designated to isolate them.

On January 23, 2020, Chinese authorities closed off the city, canceling planes and trains leaving Wuhan and suspending buses, subways and ferry services.  A second city in China, Huanggang was also placed in lockdown. On January 24, 2020 travel was restricted to a total of 10 cities, affecting 50 million people. Public bus, railway and airline operations were also suspended in these cities. On January 30, 2020 the World Health Organization (WHO) announced that the novel coronavirus is considered a public health emergency of international concern (PHEIC). The International Health Regulations Emergency Committee announcement this decision due to concern for further global spread after person-to-person spread of the novel coronavirus (COVID-19) was confirmed in 4 countries (Germany, Japan, Vietnam and the United States) outside of China. As for February 5, 2020, forty major airlines around the world have canceled or reduced their flights to China until as late as March amid the coronavirus outbreak. On February 19 and 21, 2020; cases were reported in Iran and Italy respectively with no known direct link to Mainland China. On March 9, 2020 Italy expanded the quarantine from the Lombardy region to the entire country, as Italy’s case count surged. People throughout the country of 60 million were ordered not to travel other than for work or emergencies. South Korea and Iran have also imposed travel restrictions. On March 11, 2020 the WHO declared COVID-19 viral disease a pandemic. As of May 13, 2020 the virus had spread to 188 countries with travel bans and restrictions implemented in many countries combined with various social distancing measures (ie. school, public space closures) in an effort to slow COVID-19 spread and flatten the epidemiological curve.

Preliminary calculations for the average number of infections that each infected person may go on to cause, known as R0. This is estimated to be 2.0 to 3.0 people per infected person. In comparison to seasonal flu, which usually has an R0 of around 1.3.  

The World Health Organization announced that the fatality rate in Wuhan, China, considered the epicenter of the outbreak, is between 2% and 4%. Outside of Wuhan, it is thought to be closer to 0.7%. In a recent JAMA paper The overall case-fatality rate was 2.3%. No deaths occurred in those aged 9 years and younger, in those aged 70 to 79 years had an 8% fatality rate and those aged 80 years and older had a fatality rate of 14.8%. Children made up a 2.4% of the cases and almost none was severely ill. The fatality rate was 49% among critical cases, and elevated among those with preexisting conditions: 10.5% for people with cardiovascular disease, 7.3% for diabetes, 6.3% for chronic respiratory disease, 6% for hypertension, and 5.6% for cancer.

A conjoint review done by WHO and Chinese scientists has found that 80% of infected people had mild to moderate disease, 13.8% had severe symptoms, and 6.1% had life-threatening episodes of respiratory failure, septic shock, or organ failure. No deaths were reported among mild and severe cases. For the mild and moderate cases, it took 2 weeks on average to recover.


Surveillance for COVID-19 Infection

Provincial/Territorial public health authorities should report confirmed and probable cases of COVID-19 nationally to the Public Health Agency of Canada within 24 hours of their own notification.

PHAC Interim national case definition: Novel Coronavirus (COVID-19)

Suspect case

A person with symptoms that include two or more of:

  • Fever (signs of fever)
  • Cough (new or exacerbated chronic)
  • Sore throat
  • Runny nose
  • Headache

        And

Probable Case

A person (who has had a laboratory test):

  • with fever (over 38 degrees Celsius) or new onset of (or exacerbation of chronic) cough

    And

  • who meets the COVID-19 exposure criteria and in whom a laboratory diagnosis of COVID-19 is inconclusive.

         Or

A person (who has not had a laboratory test):

  • With fever (over 38 degrees Celsius) or new onset of (or exacerbation of chronic) cough,

    And

  • Close contact with a confirmed case of COVID-19

       Or

  • Lived in or worked in a closed facility known to be experiencing an outbreak of COVID-19 (e.g., long-term care facility, prison)

Exposure criteria

In the 14 days before onset of illness, a person who:

        Or

  • Had close contact with a person with acute respiratory illness who traveled to an affected area (including inside Canada) within 14 days prior to their onset of illness

         Or

  • Participated in a mass gathering identified as a source of exposure (e.g., conference)

        Or

  • Had laboratory exposure to biological material (e.g. primary clinical specimens, virus culture isolates) known to contain COVID-19.

Symptoms of COVID-19

Illnesses associated with the new coronavirus, named COVID-19, are similar to several respiratory illnesses and include fever, dry cough, sore throat and headache. Less frequent symptoms included coughing sputum or blood, headache and diarrhea. Most cases are considered mild to moderate with a subset experiencing more severe illness with shortness of breath and difficulty breathing.

Reported signs and symptoms include:

  • Fever
  • Coughing 
  • Difficulty breathing 
  • Pneumonia in both lungs
  • Fatigue
  • Sputum production
  • Sudden loss of taste or smell
  • Anorexia
  • Myalgia
  • Runny nose
  • Diarrhea
  • Nausea

Treatment and Vaccine for COVID-19

Currently, remdesivir (brand name Veklury) is currently the only drug authorized with conditions to treat COVID-19 in those who are hospitalized with severe symptoms.

On Nov. 18, Pfizer released updated results of its Phase 3 clinical trials, suggesting the vaccine is 95 per cent effective at preventing COVID-19, a little over a week after releasing interim results showing the vaccine may be 90 per cent effective. Moderna announced on Nov. 16 that preliminary data from its ongoing Phase 3 clinical trial shows the vaccine is 94.5 per cent effective at preventing COVID-19. On Nov 23, Astra Zeneca announced their vaccine appeared to be 70 per cent effective against the novel coronavirus.

For more information about treatment and vaccines for COVID-19, click here. Also refer to NACI Preliminary guidance on key populations for early COVID-19 immunization for public health program level vaccination guidance to plan for the efficient, effective, and equitable allocation of a COVID-19 vaccine once one is authorized and available.


Infection Prevention and Control

Prior to any patient interaction, all healthcare workers (HCWs) have a responsibility to assess the infectious risk posed to themselves and to other patients, visitors, and HCWs. This risk assessment is based on professional judgment about the clinical situation and up-to-date information on how the specific healthcare organization has designed and implemented engineering and administrative controls, along with the availability and use of personal protective equipment (PPE).

Recommendations for infection prevention and control measures for patients presenting with suspected or confirmed infection or co-infection with COVID-19 in acute care settings include:

1. Routine Practices: For all patients, at all times, in all healthcare settings including when performing a point-of-care risk assessment, and adherence to respiratory hygiene and hand hygiene.

2. Contact and Droplet Precautions (should be implemented empirically):

  • Wear gloves and a long-sleeved gown upon entering the patient's room, cubicle or designated bedspace.
  • Wear facial protection (surgical or procedure mask and eye protection, or face shield, or mask with visor attachment) when within two metres of a patient suspected or confirmed to have COVID-19 infection.

3. Airborne Precautions: When performing aerosol-generating medical procedures (AGMPs). A respirator and face/eye protection should be used by all HCWs present in a room where an AGMP is being performed on a patient suspected or confirmed to have COVID-19 infection. Whenever possible, AGMPs should be performed in an airborne infection isolation room.

As information becomes available, these recommendations will be re-evaluated and updated as needed.


Variants of the Virus that Causes COVID-19

Genetic variations of viruses such as the one that causes COVID-19 are not uncommon and many other variants of the SARS-CoV-2 virus have been previously observed around the world this year. Both new variants include mutations (i.e., changes to the genetic material in the virus) on the “spike” protein, which may result in the virus becoming more infectious and spreading more easily between people. While early data suggest that these new variants may be more transmissible, to date there is no evidence that these variants cause more severe disease symptoms or have any impact on antibody response

Multiple variants of the virus that causes COVID-19 are circulating globally:

  • The United Kingdom (UK) identified a variant called B.1.1.7 with a large number of mutations in the fall of 2020. This variant spreads more easily and quickly than other variants.
  • In South Africa, another variant called B.1.351 emerged independently of B.1.1.7. Originally detected in early October 2020, B.1.351 shares some mutations with B.1.1.7.
  • In Brazil, a variant called P.1 emerged that was first identified in travelers from Brazil, who were tested during routine screening at an airport in Japan, in early January. This variant contains a set of additional mutations that may affect its ability to be recognized by antibodies.